Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

By sjmartinez • May 15, 2024

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ; ACTIV-2/A5401 Study Team. Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial. Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. PMID: 38746756; PMCID: PMC11093219.

Tags: covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, outpatient treatment, Publications, SARS-CoV-2, subcutaneous

Race and Ethnic-Specific Burden of Aortic Valve Calcium and Its Association With Long-Term Aortic Stenosis: Multi-Ethnic Study of Atherosclerosis

Grant JK, Jha K, Marrero N, Razavi AC, Boakye E, Anchouche K, Dzaye O, Budoff MJ, Shah S, Czarny MJ, Rotter JI, Guo X, Yao[...]

Serum extracellular vesicle RNA profiles in long COVID: insights from exercise-induced gene modulation

Abbasi A, Hansen N, Palade J, Paredes D, Meechoovet B, Van Keuren-Jensen K, Pirrotte P, Stringer WW. Serum extracellular vesicle RNA profiles in long COVID:[...]

Predictors of diffuse coronary artery calcium phenotype in adults aged ≥ 75: The Atherosclerosis Risk in Communities (ARIC) study

Gami A, Zou S, Dardari ZA, Dudum R, Mok Y, Budoff MJ, Lutsey PL, Howard CM, Couper D, Matsushita K, Blaha MJ. Predictors of diffuse[...]